RESUMO
A lipid nanoemulsion (LDE) resembling low-density lipoprotein can target malignant tumours. In in vivo and clinical studies, association of chemotherapeutic agents to LDE decreased their toxicity and increased pharmacological action. Here, safety of LDE as carmustine carrier (50 mg m(-2) , intravenous) combined with vincristine and prednisone for the treatment of dogs with lymphoma was tested and compared with commercial carmustine with vincristine and prednisone. In five dogs from LDE-carmustine and six from commercial carmustine, complete remission was achieved (P > 0.05). Partial remission occurred in two dogs from each group. In both groups, the median progression-free intervals (119 and 199 days) and overall survival times (207 and 247 days) were equal. Neutropenia was observed in both groups, but no other major toxicities occurred. Therefore, no difference was observed between the treatments. LDE-carmustine was shown to be safe and effective in a drug combination protocol, which encourages larger studies to investigate the use of this novel formulation to treat canine lymphomas.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Carmustina/administração & dosagem , Doenças do Cão/tratamento farmacológico , Linfoma de Células B/veterinária , Linfoma de Células T/veterinária , Animais , Antineoplásicos Alquilantes/administração & dosagem , Antineoplásicos Alquilantes/efeitos adversos , Antineoplásicos Hormonais/administração & dosagem , Antineoplásicos Hormonais/efeitos adversos , Antineoplásicos Fitogênicos/administração & dosagem , Antineoplásicos Fitogênicos/efeitos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Brasil , Carmustina/efeitos adversos , Intervalo Livre de Doença , Doenças do Cão/diagnóstico , Cães , Emulsões Gordurosas Intravenosas/administração & dosagem , Feminino , Estimativa de Kaplan-Meier , Linfoma de Células B/diagnóstico , Linfoma de Células B/tratamento farmacológico , Linfoma de Células T/diagnóstico , Linfoma de Células T/tratamento farmacológico , Masculino , Projetos Piloto , Prednisona/administração & dosagem , Prednisona/efeitos adversos , Vincristina/administração & dosagem , Vincristina/efeitos adversosRESUMO
AIM: Infective agents may affect pregnancy outcomes by deregulating homeostasis. OBJECTIVES: The effects of Porphyromonas gingivalis infection before and at different gestation periods were evaluated. MATERIALS AND METHODS: Wistar rats infected via subcutaneous with P. gingivalis W83, one week before mating (BM), days 1 (PR1) and 11 of gestation (PR11), and controls were evaluated, and samples were obtained at the end of gestation. P. gingivalis was detected by PCR. Cytokine was determined by ELISA. RESULTS: Infected rats had lower maternal gain of weight. Implantation was not observed in 2/12 BM rats. PR11 presented more fetal-placental resorptions and lower placenta/fetus weight than controls. P. gingivalis was detected in placenta and fetus. IL-6 and TNF-α levels were higher in placenta and serum of infected groups, except for TNF-α in placenta of PR1. IL-1ß levels were higher in placenta of PR11, but lower in serum and placenta of PR1. There were no differences in IL-10 and PGE2 concentrations among the groups (P < 0.05). CONCLUSIONS: The experimental infection by P. gingivalis resulted in alterations in the gestational pattern and in fetal development. The consequences of infection at mid-gestation were more severe than at the beginning, possibly due to the induction of pro-inflammatory cytokines in the fetal compartment.
Assuntos
Infecções por Bacteroidaceae , Desenvolvimento Fetal , Porphyromonas gingivalis , Complicações Infecciosas na Gravidez , Animais , Infecções por Bacteroidaceae/sangue , DNA Bacteriano/análise , Dinoprostona/análise , Dinoprostona/sangue , Feminino , Idade Gestacional , Interleucina-1beta/análise , Interleucina-1beta/sangue , Interleucina-6/análise , Interleucina-6/sangue , Troca Materno-Fetal , Placenta/química , Placenta/microbiologia , Gravidez , Complicações Infecciosas na Gravidez/sangue , Complicações Infecciosas na Gravidez/microbiologia , Resultado da Gravidez , Ratos , Ratos Wistar , Fator de Necrose Tumoral alfa/análise , Fator de Necrose Tumoral alfa/sangueRESUMO
The aim of this study was to investigate the hematological, hemostatic and biochemical disturbances induced by the injection of Crotalus durissus terrificus venom in dogs under controlled conditions. For this purpose three groups of animals were used: an experimental group (E), which was injected i.m. with C. durissus terrificus venom (1 mg/kg); and two control groups--antivenom (AV) and control (C)--which were injected i.m. with 150 mM NaCl. Groups E and AV were treated i.v. with Crotalus antivenom 2 hours after the first injection. Serum levels of alkaline phosphatase and alanine aminotransferase were increased in groups E and AV at 24 and 48 hours after serumtherapy, respectively. The increased serum levels of myoglobin, creatine kinase and aspartate aminotransferase demonstrated that animals developed rhabdomyolysis. A persistent neutrophilic leukocytosis was already noticeable at 2 hours after envenomation and lasted even after serumtherapy. The animals of groups E and AV presented eosinopenia 24 hours after serumtherapy, and collagen-induced platelet hypoaggregation was observed without thrombocytopenia. Increased levels of fibrinogen/fibrin degradation products (FnDP/FgDP), hypofibrinogenemia, and alpha2-antiplasmin consumption were observed at 2 hours after envenomation, indicating secondary activation of fibrinolysis. Our data suggest that the biochemical and hemostatic disturbances induced by C. durissus terrificus venom in dogs are related to its myotoxic and thrombin-like activities.
Assuntos
Transtornos da Coagulação Sanguínea/sangue , Venenos de Crotalídeos/toxicidade , Crotalus , Mordeduras de Serpentes/sangue , Animais , Antivenenos/uso terapêutico , Aspartato Aminotransferases/sangue , Transtornos da Coagulação Sanguínea/etiologia , Transtornos da Coagulação Sanguínea/terapia , Testes de Química Clínica , Creatina Quinase/sangue , Cães , Masculino , Mioglobina/sangue , Rabdomiólise/sangue , Rabdomiólise/etiologia , Rabdomiólise/terapia , Mordeduras de Serpentes/complicações , Mordeduras de Serpentes/terapiaRESUMO
BACKGROUND: Sleep fragmentation can decrease the awake ventilatory control. Since patients with obstructive sleep apnea (OSA) patients exhibit sleep fragmentation linked to respiratory events, their ventilatory control could be impaired. However, most of these patients are also obese, which could conversely increase the ventilatory control. The effect of nasal continuous positive airway pressure (CPAP) on the awake ventilatory control in normocapnic OSA patients is unclear. OBJECTIVES: To study the acute effect of nasal CPAP on the awake ventilatory control in normocapnic OSA patients. METHODS: 12 normocapnic OSA patients, with an apnea/hypopnea index (AHI) >15 with moderate obesity (body mass index: 33.5 kg/m2) and normal pulmonary function tests were submitted to two polysomnography studies (diagnostic and for CPAP titration). Before and after 3 consecutive nights of nasal CPAP we analyzed the hypersomnia score and the ventilatory and the mouth occlusion pressure (P.1) responses at rest (breathing room air and a mixture of 8% CO2 + 40% O2). RESULTS: The respiratory drive of OSA patients as evaluated by P.1 was in the range of the controls of our laboratory. After nasal CPAP, a significant decrease in AHI (mean: 51.9-9.4/h) and arousal (mean: 88.7-43/h) occurred, as well as improvement in nocturnal oxyhemoglobin. There was a marginal increase in DeltaV(E)/DeltaP(ET)CO2 (mean: 1.41-1.87 liters/min/ mm Hg, p = 0.09) and a significant rise in P.1/DeltaP(ET)CO2 (mean: 0.29-0.43 cm H2O/mm Hg), a better indicator of ventilatory drive. CONCLUSIONS: Normocapnic OSA patients increased their awake ventilatory drive response to a hypercapnic and hyperoxic mixture with the use of 3 consecutive nights of nasal CPAP.
Assuntos
Respiração com Pressão Positiva , Respiração , Apneia Obstrutiva do Sono/fisiopatologia , Feminino , Humanos , Hipercapnia/fisiopatologia , Masculino , Pessoa de Meia-Idade , Testes de Função RespiratóriaRESUMO
The occurrence of Toxoplasma antibodies in domestic outpatient cats in the city of São Paulo was evaluated using the indirect immunofluorescence assay. A total of 248 blood samples obtained from male and female cats seen at the Veterinary Teaching Hospital at the University of São Paulo between February 1996 and January 1997 were tested. Of these, 17.7% were positive, with a 64 titer being detected in most animals. The frequence of Toxoplasma antibodies was significantly higher in older cats, those fed raw meat and those with free access to the outdoor environment. There was no significant difference in reactivity between males and females. We conclude that diet and free access to the outdoor environment were equally important as predisposing factors to the risk of Toxoplasma infection.
Assuntos
Anticorpos Antiprotozoários/sangue , Doenças do Gato/epidemiologia , Toxoplasma/imunologia , Toxoplasmose Animal/epidemiologia , Distribuição por Idade , Animais , Anticorpos Antiprotozoários/imunologia , Brasil/epidemiologia , Doenças do Gato/imunologia , Doenças do Gato/parasitologia , Gatos , Feminino , Técnica Indireta de Fluorescência para Anticorpo , Masculino , Distribuição por Sexo , Toxoplasmose Animal/imunologia , Toxoplasmose Animal/parasitologiaRESUMO
UNLABELLED: Beta 2-agonists are considered one of the cornerstones of the asthma therapy, but their short action requires frequent administration and an association with other broncodilators. The development of long-acting beta 2-agonists may represent an important improvement in asthma treatment. PURPOSE: The present study was designed to assess the efficacy and safety of inhaled salmeterol compared to salbutamol in patients with mild-to-moderate asthma. METHODS: After the two run-in weeks, the patients received either salmeterol 50 mg twice a day or salbutamol 200 mg four times a day, over a four week period, following a double blind, parallel group study. Sixty patients had the following inclusion criteria: FEV1 > 50% or PEFR over the past seven days > 50% of predicted normal; reversibility of FEV1 > 15%; symptoms scores > 2 (score 0 and 5) in 4 of the last seven days or PEFR variation > 15%. RESULTS: Seven patients discontinued the protocol (see methods). Of the 53 analyzable patients, 25 were of the salmeterol group and 28 of the salbutamol group. Our results showed that in the run-in period there were not differences among the groups comparing the values of FEV1 in % predicted, morning PEFR and asthma symptoms scores. The improvement rate of morning FEV1 and PEFR in patients who received salmeterol was significantly higher (p < 0.05) compared to the patients who received salbutamol, for two and four weeks of treatment. Also, the salmeterol group have shown reduction of the symptoms in the nocturnal period(significantly in the first fortnight of treatment) demonstrated by the significative increase in the symptoms improvement rate when compared salmeterol and to salbutamol groups. The number of rescue medication inhaled, side effects, heart rate, blood pressure, serum potassium dosage and electrocardiograms, did no show significative differences between the groups. CONCLUSION: This study showed that in mild to moderate asthmatic patients, salmeterol in the dosage of 100 mg/day raised the FEV1 and the morning PEF and led to pronounced decrease in the nocturnal symptoms as compared to salbutamol. The side effects were similar.
Assuntos
Albuterol/análogos & derivados , Albuterol/uso terapêutico , Asma/tratamento farmacológico , Broncodilatadores/uso terapêutico , Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Pico do Fluxo Expiratório , Xinafoato de Salmeterol , Espirometria , Estatísticas não Paramétricas , Fatores de TempoRESUMO
Os Beta2-agonistas constituem um dos pilares do tratamento da asma brônquica, porém sua curta duraçao de açao exige uso freqüente e a associaçao com outras drogas broncodilatadoras. O surgimento dos Beta2-agonistas de longa açao pode representar um avanço na terapêutica da asma brônquica. Objetivo. O presente estudo propoe-se a avaliar, em nosso meio, a eficácia e a tolerabilidade do salmeterol (SM), comparativamente ao salbutamol (SB), em pacientes com asma leve e moderada. Métodos. Após uma etapa de estabilizaçao de duas semanas, os pacientes utilizaram salmeterol 50mcg duas vezes ao dia, e salbutamol 200mcg quatro vezes ao dia, durante o período de quatro semanas, seguindo um esquema duplo cego, aleatório, de grupos paralelos. Foram estudados 60 pacientes que preencheram os seguintes critérios de inclusao: VEF1 (Volume Expiratório Forçado no 1 segundo)>50 por cento: variaçao diurna do PFE (Pico do Fluxo Expiratório) > 15 por cento ou resposta do VEF1 ao BD> 15 por cento, gradaçao de sintomas >2 (escala de 0 a 5) em quatro dos últimos sete dias. Resultados. Dos 60 pacientes estudados, sete foram excluídos no período de tratamento (ver Métodos), sendo concluído o estudo com 25 pacientes no grupo salmeterol e 28 no grupo salbutamol. No período de estabilizaçao, nao houve diferença significante entre os grupos, comparando-se os valores de VEF1 em porcentagem do prev., PFE matinal, gradaçao de sintomas e gravidade da asma. O percentual de melhora do VEF1 e do PFE matinal nos pacientes que receberam salmeterol foi significantemente mais elevado entre 2 e 4 semanas de tratamento, em relaçao aos pacientes que receberam salbutamol (p<0,05). Da mesma forma, o grupo salmeterol apresentou reduçao significante nos valores médios dos sintomas no período noturno na 1 quinzena de tratamento. Em relaçao ao número de inalaçao de socorro utilizadas, efeitos colaterais, freqüência cardíaca, pressao arterial sistêmica e dosagem de potássio, nao houve diferença significante entre os grupos. Conclusao. Este estudo demonstrou que, em pacientes com asma leve a moderada, o salmeterol na dose de 100mcg/dia elevou o VEF1, o PFE matinal e apresentou diminuiçao significantemente maior dos sintomas noturnos em relaçao aos observados no grupo salbutamol, e que a tolerância aos medicamentos estudados foi semelhante nos dois grupos.
Assuntos
Feminino , Humanos , Pessoa de Meia-Idade , Adulto , Asma/tratamento farmacológico , Broncodilatadores/uso terapêutico , Agonistas Adrenérgicos beta/uso terapêutico , Albuterol/análogos & derivados , Albuterol/uso terapêutico , Espirometria , Fatores de Tempo , Quimioterapia Assistida por Computador , Broncodilatadores , Pico do Fluxo Expiratório , Resultado do Tratamento , Estatísticas não Paramétricas , Agonistas Adrenérgicos beta , Albuterol , Tolerância a MedicamentosRESUMO
In the evaluation of exercise intolerance of patients with respiratory diseases the American Medical Association (AMA) and the American Thoracic Society (ATS) have proposed similar classification for rating aerobic impairment using maximum oxygen uptake (VO2max) normalized for total body weight (ml min-1 kg-1). However, subjects with the same VO2max weight-corrected values may have considerably different losses of aerobic performance (VO2max expressed as % predicted). We have proposed a new, specific method for rating loss of aerobic capacity (VO2max, % predicted) and we have compared the two classifications in a prospective study involving 75 silicotic claimants. Logistic regression analysis showed that the disagreement between rating systems (higher dysfunction by the AMA/ATS classification) was associated with age > 50 years (P < 0.005) and overweight (P = 0.04). Interestingly, clinical (dyspnea score) and spirometric (FEV1) normality were only associated with the VO2max, % predicted, normal values (P < 0.01); therefore, in older and obese subjects the AMA/ATS classification tended to overestimate the aerobic dysfunction. We conclude that in the evaluation of aerobic impairment in patients with respiratory diseases, the loss of aerobic capacity (VO2max, % predicted) should be used instead of the traditional method (remaining aerobic ability, VO2max, in ml min-1 kg-1).
Assuntos
Avaliação da Deficiência , Tolerância ao Exercício , Exercício Físico , Consumo de Oxigênio , Doenças Respiratórias/fisiopatologia , Feminino , Humanos , Capacidade Inspiratória , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Testes de Função RespiratóriaRESUMO
In the evaluation of exercise intolerance of patients with respiratory diseases the American Medical Association (AMA) and the American Thoracic Society (ATS) have proposed similar classifications for rating aerobic impairment using maximum oxygen uptake (VO2max) normalized for total body weight (ml min(-1) kg(-1)).However, subjects with the same VO2max weight-corrected values may have considerably different losses of aerobic performance (VO2max expressed as percent predicted). We have proposed a new, specific method for rating loss of aerobic capacity (VO2max, percent predicted) and we have compared the two classifications in a prospective study involving 75 silicotic claimants. Logistic regression analysis showed that the disagreement between rating systems (higher dysfunction by the AMA/ATS classification) was associated with age>50 years (P<0.005) and overweight (P=0.04). Interestingly, clinical (dyspnea score) and spirometric (FEV(1)) normality were only associated with VO2max, percent predicted, normal values (P<0.01); therefore, in older and obese subjects the AMA/ATS classification tended to overestimate the aerobic dysfunction. We conclude that in the evaluation of aerobic impairment in patients with respiratory diseases, the loss of aerobic capacity (VO2max, percent predicted) should be used instead of the traditional method (remaining aerobic ability, VO2max, in ml min(-1) Kg(-1)).
Assuntos
Humanos , Masculino , Feminino , Pessoa de Meia-Idade , Avaliação da Deficiência , Exercício Físico , Tolerância ao Exercício , Consumo de Oxigênio , Doenças Respiratórias/fisiopatologia , Capacidade Inspiratória , Estudos Prospectivos , Testes de Função RespiratóriaRESUMO
Foram avaliadas, pela técnica de imunofluorescência indireta, a freqüência e a magnitude dos títulos de anticorpos antitoxoplasma (Toxoplasma gondii, Nicolle; Manceaux, 1909), em gatos infectados naturalmente pelo vírus da imunodeficiência dos felinos (VIF). Utilizaram-se 115 amostras de soro sangüíneo de gatos negativos ao vírus da leucemia felina que foram divididas em 3 grupos. Os 22 animais do grupo I eram positivos ao VIF. Os 58 animais que compuseram o grupo II eram doentes porém negativos na pesquisa de anticorpos anti-VIF e os 35 felinos do grupo III em hígidos e negativos ao VIF. Os resultados obtidos permitiram concluir que a freqüência de anticorpos antitoxoplasma foi maior no grupo I do que nos grupos II e III. A análise estatística mostrou forte associaçäo entre a infecçäo pelo VIF e a presença de anticorpos antitoxoplasma. Näo se observou diferença entre a magnitude dos títulos de anticorpos antitoxoplasma nos animais positivos e negativos ao VIF. Embora gatos que desenvolvam imunidade raramente eliminem oocistos, näo se sabe exatamente como esta imunidade pode influenciar a eliminaçäo de oocistos naqueles gatos infectados pelo VIF. Em face da alta freqüência de anticorpos antitoxoplasma observada nos animais positivos ao VIF, acredita-se que todos os gatos positivos a esse vírus devam ser avaliados quanto à presença de anticorpos antitoxoplasma